Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Completed 3Unknown 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 5Chemotherapy-induced Neutropenia 4Neoplasms 3Lung Neoplasms 2Urinary Bladder Neoplasms 1Small Cell Lung Cancer Extensive Stage 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma 1Carcinoma, Renal Cell 1

Interventions

pegfilgrastim 7NPI 2358 4Granulocyte Colony-Stimulating Factor 3Doxorubicin 3Docetaxel 3balugrastim 2Drug Therapy 2Cyclophosphamide 2pegylated granulocyte colony-stimulating factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Chemotherapy-induced Neutropenia × NPI 2358 × Clear all
NCT03102606 2024-08-29

Protective-1

BeyondSpring Pharmaceuticals Inc.

Phase 3 Completed
105 enrolled 16 charts

Chemotherapy-induced Neutropenia

NCT04345900 2024-05-16

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2

BeyondSpring Pharmaceuticals Inc.

Phase 2 Completed
55 enrolled 21 charts

Chemotherapy-induced Neutropenia

NCT03294577 2021-01-15

Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia

BeyondSpring Pharmaceuticals Inc.

Phase 3 Unknown
221 enrolled

Chemotherapy-induced Neutropenia

NCT04227990 2020-01-18

Plinabulin iv Solution in Prevention of TAC Induced Neutropenia

BeyondSpring Pharmaceuticals Inc.

Phase 2 Completed
115 enrolled

Chemotherapy-induced Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡